MedPath

SOLIQUA

SOLIQUA

Approved
DIN Number

02478293

Drug Class

Human

Market Date

Sep 12, 2018

Company
HC

sanofi-aventis canada inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02478293
AIG Number0260350001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
A10AE54 INSULIN GLARGINE AND LIXISENATIDE
Product Specifications
Dosage FormSolution
Route of AdministrationSubcutaneous
AHFS Classification68:20.08
Health Canada Classification

ACTIVE INGREDIENTS (2)

INSULIN GLARGINEActive
Strength: 100 UNIT / ML
Monograph: INSULIN GLARGINE
LIXISENATIDEActive
Strength: 33 MCG / ML
Monograph: LIXISENATIDE

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.